#1 Clinical Trials Search in Europe

Sodium Alginate

Clinical trials are investigating Sodium Alginate as part of treatment strategies for heartburn, reflux, and functional dyspepsia. The main goal is to see whether an alginate-based approach can help people who are using proton pump inhibitors long term without a clear need. These studies focus on treatment success, patient satisfaction, and willingness to continue therapy.

Table of contents

Trial overview

The clinical trial identified for Sodium Alginate was the PEPPER trial, also called the Primary carE PPi dEprescRibing trial.[1] It was designed to study better ways to reduce or stop long-term proton pump inhibitor use in people who did not have a clear reason to stay on these medicines for a long time.[1]

The trial compared three strategies: on-demand PPI use, replacement of PPI therapy with an alginate formulation, and a standard gradual dose reduction approach.[1] The study was completed and included 745 participants.[1]

Who was studied

The study focused on patients who were chronically using PPIs without an established indication for long-term use.[1] The conditions listed in the trial were heartburn, functional dyspepsia, and reflux.[1]

These are common upper digestive symptoms. Heartburn is a burning feeling, reflux means stomach contents moving upward, and functional dyspepsia refers to ongoing indigestion-like discomfort without a clear structural cause.[1]

What was tested

The trial tested whether replacing PPI therapy with an alginate formulation could be a good deprescribing strategy.[1] In simple terms, deprescribing means carefully reducing or stopping a medicine that may no longer be needed.[1]

Three approaches were compared. Approach A was on-demand PPI use, meaning patients would take the medicine only when needed.[1] Approach B was replacement of PPI therapy with an alginate formulation.[1] Approach C was the standard method of gradually lowering the PPI dose through fixed intermittent intake.[1]

The study hypothesis was that the two newer strategies, on-demand PPI use and alginate replacement, would perform better than the standard gradual reduction approach.[1] It was also expected that on-demand PPI use would not be worse than alginate replacement.[1]

Trial phase and design

This was an interventional study, which means the researchers assigned treatment strategies and then compared the results.[1] It was a Phase 3 trial, which usually means the treatment strategy is being tested in a larger group to see how well it works in real patients.[1]

The trial enrolled 745 patients, which makes it a fairly large study for this type of question.[1] The study is now listed as completed.[1]

Outcomes measured

The main outcome was the percentage of randomized patients who achieved a successful therapeutic outcome by the end of follow-up.[1] A randomized trial assigns people to groups by chance so the groups can be compared fairly.[1]

Successful therapeutic outcome was based on three patient-reported points: use of PPI, treatment satisfaction, and willingness to continue the treatment.[1] This means the study did not only look at symptoms or medicine use, but also at how people felt about the treatment plan and whether they wanted to keep using it.[1]

What the results meant for the study plan

The trial was built to answer a practical question in primary care: which way of reducing long-term PPI use works best for patients who may not need to stay on it forever.[1] The comparison of alginate replacement with on-demand PPI use and gradual dose reduction was meant to guide deprescribing choices.[1]

Because the study focused on patient-reported success, it gives importance to everyday experience, not only medical decisions made by researchers.[1] That makes the trial especially relevant for people living with ongoing upper digestive symptoms who are trying to find a simpler long-term treatment plan.[1]

Trial ID Phase Condition studied Status Enrollment
NCT05629143 Phase 3 Heartburn, functional dyspepsia, reflux Completed 745

FAQ

  • What is being studied in Sodium Alginate trials? The trial is studying whether switching to an alginate formulation can help people who are trying to stop long-term proton pump inhibitor use. It compares this approach with on-demand PPI use and gradual dose reduction.
  • Who can take part in these trials? The study focuses on patients who are using proton pump inhibitors chronically without a clear reason for long-term use. It also includes people with heartburn, reflux, or functional dyspepsia.
  • What phase is the trial? This study is a Phase 3 trial. Phase 3 studies usually test how well a treatment strategy works in a larger group of patients.
  • What outcomes are researchers measuring? Researchers are measuring the percentage of patients who have a successful therapeutic outcome. This is based on three patient-reported points: PPI use, treatment satisfaction, and willingness to continue treatment.
  • Is the trial completed? Yes, the trial is listed as completed. That means the planned study activities have already finished.

Ongoing Clinical Trials on Sodium Alginate

  • Study on Reducing Proton Pump Inhibitor Use in Patients with Heartburn, Reflux, or Dyspepsia: Comparing On-Demand Use, Alginate Therapy, and Gradual Dose Reduction

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium

Glossary

  • Alginate formulation: A treatment form used in the study as a replacement strategy for PPI therapy. In this trial, it is part of the treatment plan being compared with other approaches.
  • Heartburn: A burning feeling in the chest or upper stomach area. It is one of the conditions studied in this trial.
  • Reflux: When stomach contents move back upward, often causing discomfort. This is one of the conditions studied in the trial.
  • Functional dyspepsia: Ongoing upper stomach discomfort or indigestion without a clear structural cause. It is one of the conditions included in the study.
  • Proton pump inhibitors (PPIs): A group of medicines often used to reduce stomach acid. In this trial, researchers are studying ways to reduce or stop long-term use when there is no established need.
  • Deprescribing: A planned and careful way of reducing or stopping a medicine that may no longer be needed.
  • On-demand use: Taking a medicine only when symptoms appear, instead of taking it every day.
  • Randomized: Participants are assigned to a treatment group by chance, so the groups can be compared fairly.
  • Therapeutic outcome: The result of treatment. In this study, it is based on patient-reported use of PPI, satisfaction, and willingness to continue.

References